Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
Public ClinicalTrials.gov record NCT02539719. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b Dose Escalation and Expansion Study of SC-003 as a Single-Agent and in Combination With ABBV-181 in Subjects With Platinum-Resistant/ Refractory Ovarian Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1a/1b study of SC-003 as a single agent and in combination with ABBV-181 in patients with platinum-resistant/refractory ovarian cancer. SC-003 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. ABBV-181 is a humanized, recombinant, mAb that binds to cell surface expressed programmed cell death 1 (PD-1).
Study identification
- NCT ID
- NCT02539719
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2015 (Type not available)
- Primary completion
- Jan 2, 2019 (Actual)
- Completion
- Jan 2, 2019 (Actual)
- Last update posted
- Jan 4, 2019
2015 – 2019
United States locations
- U.S. sites
- 16
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Fayetteville | Arkansas | 72703 | — |
| Not listed | Duarte | California | 91010 | — |
| Not listed | Chicago | Illinois | 60637 | — |
| Not listed | Evanston | Illinois | 60208 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Detroit | Michigan | 48201 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Rochester | Minnesota | 55905 | — |
| Not listed | St Louis | Missouri | 63130 | — |
| Not listed | New York | New York | 10065 | — |
| Not listed | Columbus | Ohio | 43210 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Philadelphia | Pennsylvania | 19111 | — |
| Not listed | Nashville | Tennessee | 37203 | — |
| Not listed | Dallas | Texas | 75230 | — |
| Not listed | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02539719, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 4, 2019 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02539719 live on ClinicalTrials.gov.